CN113015520A - 含有免疫调节剂的缓释药物组合物及其用途 - Google Patents

含有免疫调节剂的缓释药物组合物及其用途 Download PDF

Info

Publication number
CN113015520A
CN113015520A CN201980061938.5A CN201980061938A CN113015520A CN 113015520 A CN113015520 A CN 113015520A CN 201980061938 A CN201980061938 A CN 201980061938A CN 113015520 A CN113015520 A CN 113015520A
Authority
CN
China
Prior art keywords
pharmaceutical composition
lipid
fingolimod
bilayer membrane
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980061938.5A
Other languages
English (en)
Chinese (zh)
Inventor
洪基隆
沃尔特.高特尼
方元成
高颢文
林宜谕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Original Assignee
Taiwan Liposome Co Ltd
TLC Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, TLC Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of CN113015520A publication Critical patent/CN113015520A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980061938.5A 2018-10-17 2019-10-15 含有免疫调节剂的缓释药物组合物及其用途 Pending CN113015520A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746810P 2018-10-17 2018-10-17
US62/746,810 2018-10-17
PCT/US2019/056186 WO2020081485A1 (en) 2018-10-17 2019-10-15 Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof

Publications (1)

Publication Number Publication Date
CN113015520A true CN113015520A (zh) 2021-06-22

Family

ID=70284157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980061938.5A Pending CN113015520A (zh) 2018-10-17 2019-10-15 含有免疫调节剂的缓释药物组合物及其用途

Country Status (6)

Country Link
US (1) US12274785B2 (cg-RX-API-DMAC7.html)
EP (1) EP3866764A4 (cg-RX-API-DMAC7.html)
JP (1) JP7477844B2 (cg-RX-API-DMAC7.html)
CN (1) CN113015520A (cg-RX-API-DMAC7.html)
TW (1) TWI767149B (cg-RX-API-DMAC7.html)
WO (1) WO2020081485A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101756902A (zh) * 2008-12-23 2010-06-30 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
CN108354904A (zh) * 2018-05-21 2018-08-03 天津双硕医药科技有限公司 一种含有盐酸金刚烷胺的口服药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
CN101199505B (zh) * 2007-12-20 2012-05-23 沈阳药科大学 维拉帕米脂质体及其制备方法
CN101601654B (zh) 2009-07-03 2010-08-18 王明 盐酸法舒地尔脂质体注射剂及其新应用
CN102406606B (zh) 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
JPWO2013176223A1 (ja) * 2012-05-23 2016-01-14 国立大学法人大阪大学 炎症性疾患治療用医薬組成物
EP2968145A1 (en) 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
CN109350600B (zh) 2013-03-15 2021-10-29 台湾微脂体股份有限公司 设计脂质体水相和非水相部分的组成来控制药物的释放趋势
CN106999419A (zh) * 2014-08-04 2017-08-01 佐尼奥尼制药股份有限公司 远程装载略微水溶性药物至脂质膜泡
US9931298B2 (en) 2015-05-26 2018-04-03 Comfort Care For Animals Llc Liposome loading
WO2017120537A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
WO2019082139A1 (en) 2017-10-27 2019-05-02 Shilpa Medicare Limited LIPOSOMAL FINGOLIMOD HYDROCHLORIDE INJECTION
WO2020023445A1 (en) 2018-07-24 2020-01-30 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101756902A (zh) * 2008-12-23 2010-06-30 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
CN108354904A (zh) * 2018-05-21 2018-08-03 天津双硕医药科技有限公司 一种含有盐酸金刚烷胺的口服药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JITENDRIYA SWAIN等: "Study of aqueous phase aggregation of FTY720 (fingolimod hydrochloride) and its effect on DMPC liposomes using fluorescent molecular probes", 《PHYS. CHEM. CHEM. PHYS.》 *
NESRINE S. EL-MEZAYEN等: "Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis", 《JOURNAL OF CONTROLLED RELEASE》 *
YUVAL AVNIR等: "Amphipathic Weak Acid Glucocorticoid Prodrugs Remote-Loaded Into Sterically Stabilized Nanoliposomes Evaluated in Arthritic Rats and in a Beagle Dog", 《ARTHRITIS & RHEUMATISM》 *
侯婷等: "硫酸铵梯度法制备脂质体的研究进展", 《中国药师》 *

Also Published As

Publication number Publication date
US12274785B2 (en) 2025-04-15
TW202033184A (zh) 2020-09-16
JP7477844B2 (ja) 2024-05-02
TWI767149B (zh) 2022-06-11
JP2022505378A (ja) 2022-01-14
EP3866764A4 (en) 2022-07-13
US20210393524A1 (en) 2021-12-23
WO2020081485A1 (en) 2020-04-23
EP3866764A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
TWI776076B (zh) 含有治療失智症之治療劑的緩釋藥物組合物及其用途
TWI755629B (zh) 含鎮靜藥物之緩釋藥物組合物及其用途
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
CN112654345A (zh) 缓释眼用药物组合物及其用途
TWI772664B (zh) 含有抗精神病藥物的緩釋藥物組合物及其用途
TWI767149B (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40054350A (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
TWI729562B (zh) 包含用於治療因骨密度降低或軟骨損失導致之疾病的治療劑的緩釋藥物組合物及其用途
TWI850208B (zh) 緩釋型翠普登組成物及其經皮下或類似途徑使用之方法
HK40043627A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
HK40046574A (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
HK40045697A (en) Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
HK40054349A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
HK40046579A (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40054350

Country of ref document: HK